SHR-2017 / Jiangsu Hengrui Pharma - LARVOL DELTA

A Trial of SHR-2017 Injection in Patients With Bone Metastases From Solid Tumors (clinicaltrials.gov) - P2 | N=210 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P2 trial • Oncology • Solid Tumor

A phase 1b study of SHR-2017, a RANKL/NGF targeted antibody, in patients (pts) with breast cancer bone metastasis. (ASCO 2025) - P1 | "Preliminary data indicated promising anti-bone resorption and analgesic effects, with a favorable safety profile for SHR-2017 in pts with bone metastasis from breast cancer. The trial is ongoing to further evaluate SHR-2017 following multiple dosing."

Clinical • P1 data • Breast Cancer • Oncology • Pain • Solid Tumor

PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases (clinicaltrials.gov) - P1 | N=20 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

PK/PD Study of SHR-2017 Injection in Patients With Bone Metastases (clinicaltrials.gov) - P1 | N=20 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P1 trial • Oncology • Solid Tumor

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Osteoporosis • Rheumatology

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SHR-2017 Injection in Postmenopausal Women (clinicaltrials.gov) - P1 | N=45 | Not yet recruiting | Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.

New P1 trial • Osteoporosis • Rheumatology

Hengrui Medicine (600276.SH): SHR-2017 Injection Approved for Clinical Trials [Google translation] (Zhitong Finance) - "Zhitong Finance APP news, Hengrui Medicine...announced that recently, the company's subsidiary Suzhou Shengdia Biomedical Co., Ltd. received the approval and issuance of the SHR-2017 injection The 'Notice of Approval of Clinical Trials of Drugs' issued by the company agreed to carry out clinical trials for the prevention indications of bone-related events in patients with bone metastases from solid tumors and multiple myeloma patients."

New trial • Hematological Malignancies • Multiple Myeloma • Oncology • Solid Tumor